Tenecteplase, 0.4 mg/kg, in Moderate and Severe Acute Ischemic Stroke: A Pooled Analysis of NOR‐TEST and NOR‐TEST 2A

Background The optimal dose of tenecteplase in acute ischemic stroke remains to be defined. We present a pooled analysis of the 2 NOR‐TESTs (Norwegian Tenecteplase Stroke Trials) exploring the efficacy and safety of tenecteplase, 0.4 mg/kg. Methods and Results We retrospectively reviewed 2 PROBE (Pr...

Descripció completa

Dades bibliogràfiques

Autors principals:	Vojtech Novotny, Christopher Elnan Kvistad, Halvor Naess, Nicola Logallo, Annette Fromm, Andrej Netland Khanevski, Lars Thomassen
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2023-10-01
Col·lecció:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Matèries:	clinical trial ischemic stroke tenecteplase thrombolytic therapy tissue plasminogen activator
Accés en línia:	https://www.ahajournals.org/doi/10.1161/JAHA.123.030320
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!